Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases

Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases: A Randomized Trial

The purpose of this study is to evaluate the safety profile and efficacy of whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ) in patients with brain metastases (BM).Patients with BM were randomly assigned to 30 Gy of WBRT with or without concomitant TMZ (75 mg/m2/d) plus two cycles of TMZ (200 mg/m2/d for 5 days).

Inclusion Criteria:

• histologically diagnosed as NSCLC, stage IVb [ (American Joint of Cancer Committee(AJCC), 2002) ], Brain metastasis
• no history of hypertension or diabetes.

Exclusion Criteria:

• the brain tumor diameter >5cm; RPA class =3; pregnancy.